Pharma Exclusives Pressreleases
Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)
Monday, July 14, 2025Boehringer Ingelheim and LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of SPEVIGO spesolimab
Bayer receives first approval worldwide for Lynkuet™ (elinzanetant) in the UK as treatment of moderate to severe vasomotor symptoms associated with menopause
Friday, July 11, 2025Bayer today announced that the Medicines and Healthcare products Regulatory Agency MHRA regulatory authority in the UK has authorized the use of elinzanetant the first dual neurokinin NKtargeted therapy
Bayer files for EU approval of gadoquatrane
Thursday, July 10, 2025Bayer today announced the submission of a marketing authorization application to the European Medicines Agency for its investigational contrast agent gadoquatrane for contrast enhancement in magnetic resonance imaging
Hongene Supports Clinical Advancement of siRNA DNV001 Using Proprietary Chemoenzymatic Ligation Platform
Thursday, July 10, 2025Hongene Biotech Corporation a contract development and manufacturing organization CDMO specializing in nucleic acid therapeutics today announced its critical role in advancing DNV
BioMed X and Servier Launch First XSeed Labs in Europe
Wednesday, July 09, 2025BioMed X an independent biomedical research institute based in Heidelberg Germany announced today the launch of a new initiative with Servier The two partners will implement BioMed Xs proven XSeed Labs incubator model at Serviers
Ofichem acquires Avivia B.V. to expand formulation development capabilities
Wednesday, July 09, 2025Ofichem Group has signed a definitive agreement to acquire Avivia BV a company specialized in formulation development based in Nijmegen the Netherlands
HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure
Monday, July 07, 2025HeartBeatbio AG and biotxai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure The collaboration combines biotxais causal mapping
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Thursday, July 03, 2025Neurizon Therapeutics Limited a clinicalstage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases is pleased to announce it has executed an exclusive global license
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
Monday, June 30, 2025Hansa Biopharma AB Hansa announced today the presentation of its five year extended pooled analysis including data from the HMedIdeS study an international longterm followup study of patients who have received
UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder
Friday, June 27, 2025UCB a global biopharmaceutical company today announced that the phase study investigating the safety and efficacy of adjunctive fenfluramine in CDKL Deficiency Disorder CDD met its primary and key secondary endpoints
